Showing 9,241 - 9,260 results of 18,262 for search 'significantly ((((linear decrease) OR (((we decrease) OR (a decrease))))) OR (larger decrease))', query time: 0.88s Refine Results
  1. 9241

    Image 3_Effects of gender affirming hormone therapy with testosterone on renal function of assigned female at birth transgender people: a meta-analysis.tif by Daniele Tienforti (11665717)

    Published 2025
    “…The pooled estimates documented a significant decrease in eGFR (CKD-EPI equation) at 6 and 12 months with respect to baseline, using the attributed (female) gender. …”
  2. 9242

    Image 1_Effects of gender affirming hormone therapy with testosterone on renal function of assigned female at birth transgender people: a meta-analysis.tif by Daniele Tienforti (11665717)

    Published 2025
    “…The pooled estimates documented a significant decrease in eGFR (CKD-EPI equation) at 6 and 12 months with respect to baseline, using the attributed (female) gender. …”
  3. 9243

    Data Sheet 1_TREM-1 as a potential gatekeeper of neuroinflammatory responses: therapeutic validation and mechanistic insights in experimental traumatic brain injury.zip by Yunsheng Zhang (474242)

    Published 2025
    “…Background<p>Traumatic brain injury (TBI) triggers a cascade of neuroinflammatory responses mediated by microglial activation, which significantly contributes to secondary brain damage. …”
  4. 9244

    Image 2_Effects of gender affirming hormone therapy with testosterone on renal function of assigned female at birth transgender people: a meta-analysis.tif by Daniele Tienforti (11665717)

    Published 2025
    “…The pooled estimates documented a significant decrease in eGFR (CKD-EPI equation) at 6 and 12 months with respect to baseline, using the attributed (female) gender. …”
  5. 9245

    Image 5_Effects of gender affirming hormone therapy with testosterone on renal function of assigned female at birth transgender people: a meta-analysis.tif by Daniele Tienforti (11665717)

    Published 2025
    “…The pooled estimates documented a significant decrease in eGFR (CKD-EPI equation) at 6 and 12 months with respect to baseline, using the attributed (female) gender. …”
  6. 9246

    Table 1_Prevalence and prognostic value of sarcopenia in patients with bladder cancer undergoing radical cystectomy: a systematic review and meta-analysis.docx by Lei Zhang (38117)

    Published 2025
    “…The results of meta-analysis showed that the pooled prevalence of sarcopenia was estimated to be 49% (95% CI: 41% to 57%, I<sup>2</sup> = 95.3%, P < 0.001), which was based on a random-effects model. We observed that BC patients with sarcopenia had a worse OS (HR:1.64, 95% CI: 1.30 to 1.97, I<sup>2</sup> = 76.5%, P < 0.001} and CSS (HR:1.86, 95% CI: 1.45 to 2.27, I<sup>2</sup> = 0.0%, P < 0.001).…”
  7. 9247

    Image 1_A four-gene signature identified by integrated transcriptomic analysis for differential diagnosis and prognosis of uterine smooth muscle tumors.pdf by Huiyi Hu (11226995)

    Published 2025
    “…Moreover, survival analysis revealed the prognostic significance of this four-gene signature: high TOP2A with low ABLIM1, FHL5, and MAP3K8 expression correlated with decreased overall survival in ULMS, implicating their potential role as diagnostic and prognostic markers. …”
  8. 9248

    Data Sheet 1_The relationship between intrinsic capacity and sarcopenia in middle-aged and older Chinese populations: the mediating influence of a novel nutritional index.zip by Hong Ding (135247)

    Published 2025
    “…Higher TCBI was associated with a 28% decrease in sarcopenia risk per unit increase (OR = 0.72, 95% CI: 0.58–0.90, p = 0.004). …”
  9. 9249

    Data Sheet 1_Impact of meteorological factors on influenza incidence in Wuxi from 2014 to 2019: a time series and comprehensive analysis.docx by Menglan He (3768739)

    Published 2025
    “…The exposure-response relationship was analyzed using a generalized additive model. Then we performed subgroup analysis based on age and gender. …”
  10. 9250

    Data Sheet 1_Burden of falls in China, 1992–2021 and projections to 2030: a systematic analysis for the global burden of disease study 2021.xlsx by Liang Sui (20912441)

    Published 2025
    “…Joinpoint regression analysis revealed fluctuating trends in prevalence and incidence with periods of increase and decline, and a general decrease in mortality except during brief intervals. …”
  11. 9251

    Data_Sheet_1_Neuroprotection by upregulation of the major histocompatibility complex class I (MHC I) in SOD1G93A mice.docx by Ana Laura M. R. Tomiyama (16902930)

    Published 2024
    “…Disease progression upregulated gene transcripts for pro- and anti-inflammatory cytokines, and IFN β treatment significantly decreased mRNA expression for IL4. Overall, the present results demonstrate that a low dosage of IFN β shows therapeutic potential by increasing MHC-I expression, resulting in neuroprotection and immunomodulation.…”
  12. 9252
  13. 9253

    Supplementary Material for: Preliminary efficacy, tolerability, and safety analysis of Darolutamide for metastatic castration‑resistant prostate cancer: a single-center, open-label... by Yu J. (3610580)

    Published 2024
    “…The median time to PSA50 in the Darolutamide group was 1.5 months (95%CI 0.2619- 0.9545), significantly lower than that in the placebo group (3.0 months [95%CI 1.048- 3.818], p= 0.0259); The median time to PSA90 in the experimental group was 4 months (95%CI 0.3094- 1.437), 2 months shorter than that in the placebo group (6.0 months [95%CI 0.6961- 3.232]).With the median follow-up of 6 months, , the median decrease in serum PSA was -81.8% (range -60.4 to -99.9%) in the Darolutamide group and -69.4% (range -50.3 to -89.6%) in the placebo group. …”
  14. 9254

    Data Sheet 3_Association between sarcopenia and outcomes of surgically treated oral squamous cell carcinoma: a systematic review and meta‐analysis.pdf by Kai Luo (769190)

    Published 2024
    “…Background<p>Sarcopenia is a significant predictor of perioperative adverse outcomes for a variety of malignancies and has significant negative effects on surgical and oncology outcomes. …”
  15. 9255

    Data Sheet 2_Association between sarcopenia and outcomes of surgically treated oral squamous cell carcinoma: a systematic review and meta‐analysis.pdf by Kai Luo (769190)

    Published 2024
    “…Background<p>Sarcopenia is a significant predictor of perioperative adverse outcomes for a variety of malignancies and has significant negative effects on surgical and oncology outcomes. …”
  16. 9256

    Data Sheet 1_Association between sarcopenia and outcomes of surgically treated oral squamous cell carcinoma: a systematic review and meta‐analysis.pdf by Kai Luo (769190)

    Published 2024
    “…Background<p>Sarcopenia is a significant predictor of perioperative adverse outcomes for a variety of malignancies and has significant negative effects on surgical and oncology outcomes. …”
  17. 9257

    Data Sheet 4_Association between sarcopenia and outcomes of surgically treated oral squamous cell carcinoma: a systematic review and meta‐analysis.pdf by Kai Luo (769190)

    Published 2024
    “…Background<p>Sarcopenia is a significant predictor of perioperative adverse outcomes for a variety of malignancies and has significant negative effects on surgical and oncology outcomes. …”
  18. 9258

    Data Sheet 1_Breaking the cancer code: a novel DNA minicircle to disable STAT3 in ovarian cancer cells SKOV3.docx by Adina-Gabriela Vasilescu (22236073)

    Published 2025
    “…Introduction<p>Ovarian Cancer remains a significant global health concern, with high mortality rates, largely due to late-stage diagnosis and limited treatment options. …”
  19. 9259

    Supplementary tables: Assessing healthcare resource utilization burden and unmet treatment needs in patients with Parkinson’s disease: results from a real-world study by Malgorzata Ciepielewska (22143499)

    Published 2025
    “…The intermediate versus early group had a significantly greater proportion of patients with unmet treatment needs (p < 0.001), e.g., slowing disease progression, providing neuroprotection. …”
  20. 9260

    Data Sheet 1_Glucocorticoids and immunoglobulin alone or in combination in the treatment of multisystemic inflammatory syndrome in children: a systematic review and network meta-an... by Junjie Lin (8379594)

    Published 2025
    “…When compared to combination therapy, GCs monotherapy was associated with a reduction in ICU length of stay [SMD −0.25, 95% CI (−0.85, 0.36)], duration of fever (SMD [−0.42, 95% CI (−0.73, −0.11)], and duration of inotropic support [SMD −0.13, 95% CI (−0.46, 0.20)], as well as a decrease in the incidence of left ventricular (LV) dysfunction [OR 0.96, 95% CI (0.55, 1.68)]. …”